Literature DB >> 9174174

SCH 48973: a potent, broad-spectrum, antienterovirus compound.

P J Buontempo1, S Cox, J Wright-Minogue, J L DeMartino, A M Skelton, E Ferrari, R Albin, E J Rozhon, V Girijavallabhan, J F Modlin, J F O'Connell.   

Abstract

SCH 48973 is a novel molecule with potent, selective, antienterovirus activity. In assays of the cytopathic effect against five picornaviruses, SCH 48973 had antiviral activity (50% inhibitory concentrations [IC50s]) of 0.02 to 0.11 microg/ml, with no detectable cytotoxicity at 50 microg/ml. SCH 48973 inhibited 80% of 154 recent human enterovirus isolates at an IC50 of 0.9 microg/ml. The antiviral activity of SCH 48973 is derived from its specific interaction with viral capsid, as confirmed by competition binding studies. The affinity constant (Ki) for SCH 48973 binding to poliovirus was 8.85 x 10(-8) M. In kinetic studies, a maximum of approximately 44 molecules of SCH 48973 were bound to poliovirus capsid. SCH 48973 demonstrated efficacy in a murine poliovirus model of enterovirus disease. SCH 48973 increased the survival of infected mice when it was administered orally at dosages of 3 to 20 mg/kg of body weight/day. Oral administration of SCH 48973 also reduced viral titers in the brains of infected mice. On the basis of its in vitro and in vivo profiles, SCH 48973 represents a potential candidate for therapeutic intervention against enterovirus infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174174      PMCID: PMC163890          DOI: 10.1128/AAC.41.6.1220

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.

Authors:  M P Fox; M A McKinlay; G D Diana; F J Dutko
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

2.  A comparative study of viruses associated with acute haemorrhagic conjunctivitis.

Authors:  P G Higgins; R J Scott; P M Davies; D R Gamble
Journal:  J Clin Pathol       Date:  1974-04       Impact factor: 3.411

3.  Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies.

Authors:  S Cox; P J Buontempo; J Wright-Minogue; J L DeMartino; A M Skelton; E Ferrari; J Schwartz; E J Rozhon; C C Linn; V Girijavallabhan; J F O'Connell
Journal:  Antiviral Res       Date:  1996-10       Impact factor: 5.970

4.  Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.

Authors:  R B Turner; F J Dutko; N H Goldstein; G Lockwood; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  Human rhinovirus 14 complexed with antiviral compound R 61837.

Authors:  M S Chapman; I Minor; M G Rossmann; G D Diana; K Andries
Journal:  J Mol Biol       Date:  1991-02-05       Impact factor: 5.469

6.  SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.

Authors:  E Rozhon; S Cox; P Buontempo; J O'Connell; W Slater; J De Martino; J Schwartz; G Miller; E Arnold; A Zhang
Journal:  Antiviral Res       Date:  1993-05       Impact factor: 5.970

7.  Rhodanine: a selective inhibitor of the multiplication of echovirus 12.

Authors:  H J Eggers; M A Koch; A Furst; G D Daves; J J Wilczynski; K Folkers
Journal:  Science       Date:  1970-01-16       Impact factor: 47.728

8.  Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14.

Authors:  A Zhang; R G Nanni; T Li; G F Arnold; D A Oren; A Jacobo-Molina; R L Williams; G Kamer; D A Rubenstein; Y Li
Journal:  J Mol Biol       Date:  1993-04-05       Impact factor: 5.469

9.  The structure of coxsackievirus B3 at 3.5 A resolution.

Authors:  J K Muckelbauer; M Kremer; I Minor; G Diana; F J Dutko; J Groarke; D C Pevear; M G Rossmann
Journal:  Structure       Date:  1995-07-15       Impact factor: 5.006

10.  The structure of human rhinovirus 16.

Authors:  M A Oliveira; R Zhao; W M Lee; M J Kremer; I Minor; R R Rueckert; G D Diana; D C Pevear; F J Dutko; M A McKinlay
Journal:  Structure       Date:  1993-09-15       Impact factor: 5.006

View more
  15 in total

Review 1.  Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.

Authors:  Anna Egorova; Sean Ekins; Michaela Schmidtke; Vadim Makarov
Journal:  Eur J Med Chem       Date:  2019-06-11       Impact factor: 6.514

2.  Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

Authors:  Hong-Mei Liu; Jason A Roberts; Deborah Moore; Barbara Anderson; Mark A Pallansch; Daniel C Pevear; Marc S Collett; M Steven Oberste
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  In vitro antiviral activity of V-073 against polioviruses.

Authors:  M Steven Oberste; Deborah Moore; Barbara Anderson; Mark A Pallansch; Daniel C Pevear; Marc S Collett
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

4.  Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.

Authors:  Minetaro Arita; Hirotatsu Kojima; Tetsuo Nagano; Takayoshi Okabe; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

5.  Dominant drug targets suppress the emergence of antiviral resistance.

Authors:  Elizabeth J Tanner; Hong-mei Liu; M Steven Oberste; Mark Pallansch; Marc S Collett; Karla Kirkegaard
Journal:  Elife       Date:  2014-11-03       Impact factor: 8.140

6.  Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.

Authors:  Marc S Collett; Jeffrey R Hincks; Kimberley Benschop; Erwin Duizer; Harrie van der Avoort; Eric Rhoden; Hongmei Liu; M Steven Oberste; Mark A McKinlay; Marianne Hartford
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

7.  Neonatal Enterovirus Myocarditis With Severe Dystrophic Calcification: Novel Treatment With Pocapavir.

Authors:  Samuel G Wittekind; Catherine C Allen; John L Jefferies; Mantosh S Rattan; Peace C Madueme; BreAnn N Taylor; Ryan A Moore
Journal:  J Investig Med High Impact Case Rep       Date:  2017-09-14

Review 8.  Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules.

Authors:  Shin-Ru Shih; Shu-Jen Chen; Gholam Hossein Hakimelahi; Hsing-Jang Liu; Chen-Tso Tseng; Kak-Shan Shia
Journal:  Med Res Rev       Date:  2004-07       Impact factor: 12.944

Review 9.  Replication and Inhibitors of Enteroviruses and Parechoviruses.

Authors:  Lonneke van der Linden; Katja C Wolthers; Frank J M van Kuppeveld
Journal:  Viruses       Date:  2015-08-10       Impact factor: 5.048

10.  Fexaramine as an entry blocker for feline caliciviruses.

Authors:  Yunjeong Kim; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2018-02-15       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.